A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
NCT ID: NCT00073151
Last Updated: 2007-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
30 participants
INTERVENTIONAL
2003-09-30
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-751
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recurrent tumor following treatment with paclitaxel or docetaxel.
* Able to tolerate normal activities of daily living.
* Adequate bone marrow, kidney and liver function.
Exclusion Criteria
* Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
* CNS metastasis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen Eliopoulos, MD
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncology Hematology Group of South Florida
Miami, Florida, United States
Florida Cancer Institute
New Port Richey, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
Oncology & Hematology Associates of Kansas City, PA
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Albany Regional Cancer Center
Albany, New York, United States
Raleigh Hematology Oncology
Cary, North Carolina, United States
Dayton Oncology and Hematology
Kettering, Ohio, United States
Cancer Care Associates
Oklahoma City, Oklahoma, United States
Cancer Centers of the Carolinas
Greenville, South Carolina, United States
West Cancer Clinic
Memphis, Tennessee, United States
Texas Oncology
Dallas, Texas, United States
Texas Oncology
Fort Worth, Texas, United States
Cancer Care Northwest
Spokane, Washington, United States
Northwest Cancer Specialists
Vancouver, Washington, United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M02-448
Identifier Type: -
Identifier Source: org_study_id
NCT00080730
Identifier Type: -
Identifier Source: nct_alias